**Branch revenues:**
- Hematology: approx. 60%
- Urinalysis: approx. 15%
- Immunochemistry: approx. 10%
- Hemostasis: approx. 10%
- Other diagnostic areas: approx. 5%

**TOP 3 markets:**
- Japan: approx. 30%
- North America: approx. 25%
- Europe: approx. 20%

Sysmex Corporation generates the majority of its revenues from hematology, which is attributed to its leading position in the development and manufacturing of blood analysis systems.

Japan remains the largest single market for Sysmex, followed by North America and Europe. These markets benefit from high demand for advanced diagnostic solutions and a strong distribution network.

Through continuous innovation and strategic partnerships, Sysmex has established itself as a leading provider of diagnostic solutions in these regions.

**Production sites of Sysmex Corporation:**

1. **Japan:** Main production facilities are located in Kobe and its vicinity, where a large part of the research and development as well as manufacturing takes place.

2. **Germany:** Sysmex operates production facilities in Germany, especially for the European market.

3. **USA:** There are also production capacities in the United States to serve the North American market.

4. **China:** In China, Sysmex has production plants to meet the increasing demand in the Asian market.

Sysmex Corporation is a globally operating company that strategically places its production sites in different regions to optimize logistics and ensure proximity to key markets. This enables the company to efficiently respond to regional market requirements while minimizing delivery times.

**Focus on Research and Development:** 9% of revenue (2024)

**Expansion of Product Range:** Introduction of new diagnostic tests (2024)

**Market Expansion:** Increasing presence in emerging markets (2024)

Sysmex Corporation pursues a growth strategy that is heavily based on innovation and research. The company continuously invests a significant portion of its revenue in research and development to expand its technological capabilities and develop new products.

Another focus is on expanding the product range, particularly through the introduction of new diagnostic tests that meet current medical requirements. This strategy aims to solidify market leadership in in-vitro diagnostics.

Furthermore, Sysmex is focusing on tapping into new markets, especially in emerging countries, to strengthen its global presence and capitalize on growth opportunities there. This includes both expanding distribution networks and forming strategic partnerships.

**Main raw materials:** Rare earths, precious metals, plastics

**Countries of origin:** China, South Africa, USA, Japan

Sysmex Corporation, a leading company in the field of medical diagnostics, imports various raw materials necessary for the production of their devices and systems. The most important raw materials include rare earths and precious metals, which are needed for the manufacturing of electronic components and sensors. These materials are mainly sourced from China and South Africa, as these countries are among the largest producers of rare earths and precious metals.

In addition, Sysmex imports plastics used in the production of casings and other components. The USA and Japan are important suppliers of high-quality plastics used in medical technology. These materials are crucial for the quality and reliability of Sysmex products.

**Market Share:** 20% in the field of hematology diagnostics (2024, estimate)
**R&D Expenses:** 9% of revenue (2023)
**Patent Portfolio:** Over 2,000 patents worldwide (2023)

Sysmex Corporation has a significant competitive advantage in the field of hematology diagnostics. With an estimated market share of 20%, the company is one of the leading providers in this segment.

A key factor for this advantage is the strong commitment to research and development, with 9% of revenue being invested in R&D. This enables continuous innovation and the development of new technologies.

In addition, Sysmex has an extensive patent portfolio with over 2,000 patents worldwide, ensuring the protection of their technologies and products and making it difficult for new competitors to enter the market.

These factors together strengthen Sysmex's market position and provide a sustainable competitive advantage over other companies in the industry.

**Institutional Investor Share:** approximately 60% (2025, estimated)

**Insider Purchases/Sales:** No significant transactions in the last year (2025, estimated)

The institutional investor share in Sysmex Corporation is estimated to be around 60%. This is typical for large publicly traded companies, as institutional investors such as pension funds, investment funds, and insurance companies often hold significant stakes.

Regarding insider transactions, there have been no significant purchases or sales in 2025 that would indicate a substantial change in corporate leadership or strategic realignments. This suggests a stable confidence of the management in the company's future development.

**Market share of Sysmex Corporation:** 12% (2025, estimated)

**Top competitors and their market shares:**
1. **Roche Diagnostics:** 18%
2. **Abbott Laboratories:** 15%
3. **Siemens Healthineers:** 14%
4. **Sysmex Corporation:** 12%
5. **Danaher Corporation:** 10%
6. **Thermo Fisher Scientific:** 9%
7. **Becton, Dickinson and Company:** 8%
8. **Bio-Rad Laboratories:** 5%
9. **Beckman Coulter (part of Danaher):** 4%
10. **PerkinElmer:** 3%

**Moat of Sysmex Corporation:**

Sysmex Corporation has a significant moat, primarily characterized by its specialization in hematology diagnostics and innovative technologies. The company heavily invests in research and development, leading to a continuous improvement of its products and services. This specialization and innovation give Sysmex a competitive advantage, especially in niche markets.

Compared to its competitors, who often offer a broader range of diagnostic solutions, Sysmex benefits from focusing on specific market segments. This allows for deeper customer loyalty and a stronger market presence in these areas.

However, some of the larger competitors like Roche and Abbott have a broader moat due to their comprehensive product portfolios and global reach. These companies benefit from economies of scale and a strong brand presence, enabling them to be leaders in various diagnostic areas.

**Revenue Growth:** 8.5% (2024)
**R&D Expenses:** 10% of revenue (2024)
**Market Share in the Diagnostics Industry:** 12% (2024)

Sysmex Corporation recorded a revenue growth of 8.5% in 2024, attributed to strong demand for their diagnostic solutions and successful market expansion. The company continuously invests in research and development, with 10% of revenue allocated to this area. These investments enhance Sysmex's innovation capabilities and enable the introduction of new products that could further expand market share.

Sysmex's market share in the diagnostics industry stands at 12%, positioning the company as one of the leading players in this sector. This position provides a solid foundation for further growth, especially in emerging markets and through portfolio expansion.

Overall, Sysmex demonstrates strong operational performance and innovation, making the stock a potentially attractive investment, particularly for long-term investors looking to benefit from ongoing developments in the healthcare sector.

**Dividend Yield:** 1.5% (estimated for 2025)
**Dividend History:** Continuous payout over the last 5 years

Sysmex Corporation has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 1.5% for 2025, based on the latest available data and the company's dividend policy.

The reliability of the payout can be considered high, as Sysmex has paid dividends continuously over the past five years and demonstrates stable financial performance. The solid market position and continuous revenue growth support the company's ability to continue paying dividends in the future.